Jefferies Financial Group upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a report published on Friday morning, Benzinga reports. They currently have $62.00 price objective on the stock, up from their previous price objective of $50.00. Jefferies Financial Group also issued estimates for Catalent’s Q1 2020 earnings at $0.16 EPS and Q4 2020 earnings at $0.75 EPS.

Several other research analysts have also recently commented on the company. Zacks Investment Research upgraded Catalent from a hold rating to a buy rating and set a $57.00 price target on the stock in a research note on Wednesday, June 19th. Morgan Stanley boosted their price objective on Catalent from $46.00 to $50.00 and gave the company an overweight rating in a report on Tuesday, April 16th. UBS Group raised Catalent from a neutral rating to a buy rating and boosted their price objective for the company from $43.00 to $54.00 in a report on Tuesday, April 16th. ValuEngine raised Catalent from a hold rating to a buy rating in a report on Monday, April 15th. Finally, First Analysis reissued an outperform rating and issued a $49.00 price objective on shares of Catalent in a report on Tuesday, March 5th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Catalent has an average rating of Buy and a consensus price target of $53.14.

NYSE:CTLT opened at $52.70 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.71 and a current ratio of 2.18. Catalent has a one year low of $29.23 and a one year high of $54.10. The stock has a 50-day simple moving average of $47.27. The firm has a market capitalization of $7.76 billion, a PE ratio of 33.14, a price-to-earnings-growth ratio of 2.75 and a beta of 1.57.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.07. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The business had revenue of $617.50 million for the quarter, compared to analysts’ expectations of $644.88 million. During the same quarter in the previous year, the firm posted $0.41 earnings per share. The company’s revenue was down 1.7% compared to the same quarter last year. As a group, equities research analysts expect that Catalent will post 1.72 EPS for the current fiscal year.

In related news, Director Gregory T. Lucier bought 2,000 shares of the stock in a transaction dated Thursday, May 9th. The stock was bought at an average cost of $45.08 per share, with a total value of $90,160.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $44.44 per share, with a total value of $444,400.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 56,500 shares of company stock valued at $2,542,845. 1.40% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Zions Bancorporation N.A. bought a new position in shares of Catalent during the first quarter valued at approximately $61,000. Blueshift Asset Management LLC bought a new position in shares of Catalent during the fourth quarter valued at approximately $815,000. Swiss National Bank grew its holdings in shares of Catalent by 3.4% during the first quarter. Swiss National Bank now owns 264,970 shares of the company’s stock valued at $10,755,000 after purchasing an additional 8,800 shares during the last quarter. Bernzott Capital Advisors grew its holdings in shares of Catalent by 1.0% during the fourth quarter. Bernzott Capital Advisors now owns 797,565 shares of the company’s stock valued at $24,868,000 after purchasing an additional 7,900 shares during the last quarter. Finally, Vanguard Group Inc grew its holdings in shares of Catalent by 9.4% during the third quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after purchasing an additional 1,110,779 shares during the last quarter. 96.85% of the stock is owned by institutional investors.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Front-End Load

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.